Esperion Therapeutics Inc
NASDAQ:ESPR

Watchlist Manager
Esperion Therapeutics Inc Logo
Esperion Therapeutics Inc
NASDAQ:ESPR
Watchlist
Price: 0.9936 USD -2.59% Market Closed
Market Cap: 196.9m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+45%
Revenue
Forecast
-10%
Operating Income
Forecast
-7%
Net Income
Forecast
N/A

Wall Street
Price Targets

ESPR Price Targets Summary
Esperion Therapeutics Inc

Wall Street analysts forecast ESPR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ESPR is 5.9014 USD with a low forecast of 1.515 USD and a high forecast of 16.8 USD.

ESPR Lowest Forecast
Wall Street Target
1.515 USD
52% Upside
ESPR Average Forecast
Wall Street Target
5.9014 USD
494% Upside
ESPR Highest Forecast
Wall Street Target
16.8 USD
1 591% Upside
Lowest
Price Target
1.515 USD
52% Upside
Average
Price Target
5.9014 USD
494% Upside
Highest
Price Target
16.8 USD
1 591% Upside
Esperion Therapeutics Inc Competitors:
Price Targets
600436
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
31% Upside
688321
Shenzhen Chipscreen Biosciences Co Ltd
61% Upside
4887
Sawai Group Holdings Co Ltd
37% Upside
ANCR
Animalcare Group PLC
12% Upside
600436
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
31% Upside
688321
Shenzhen Chipscreen Biosciences Co Ltd
61% Upside
4887
Sawai Group Holdings Co Ltd
37% Upside
ANCR
Animalcare Group PLC
12% Upside
G
GLENMARK
Glenmark Pharmaceuticals Ltd
1% Downside
C
2M7C
China Medical System Holdings Ltd
4% Downside
688166
BrightGene Bio-Medical Technology Co Ltd
15% Downside

Revenue
Forecast

Revenue Estimate
Esperion Therapeutics Inc

The compound annual growth rate of Esperion Therapeutics Inc's revenue for the next 3 years is 12%.

N/A
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Esperion Therapeutics Inc

The compound annual growth rate of Esperion Therapeutics Inc's operating income for the next 3 years is 11%.

N/A
Past Growth
11%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Esperion Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-86%
Average Miss
What are analyst estimates?

See Also

Summary
ESPR intrinsic value, competitors valuation, and company profile.
DCF Valuation
ESPR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ESPR stock valuation using valuation multiples.
Wall Street Estimates
ESPR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ESPR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ESPR's stock price target?
Price Target
5.9014 USD

According to Wall Street analysts, the average 1-year price target for ESPR is 5.9014 USD with a low forecast of 1.515 USD and a high forecast of 16.8 USD.

What is Esperion Therapeutics Inc's Revenue forecast?
Projected CAGR
12%

The compound annual growth rate of Esperion Therapeutics Inc's revenue for the next 3 years is 12%.

What is Esperion Therapeutics Inc's Operating Income forecast?
Projected CAGR
11%

The compound annual growth rate of Esperion Therapeutics Inc's operating income for the next 3 years is 11%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 264,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.